The recent biotech stock market is really a tale of two extremes. CRSP and NTLA in hand are still struggling, chasing the dream of gene editing but completely missing the big surge of MLTX and ELVN, watching RVMD hit new highs again, feeling really sour. The ability to tell stories in a bull market is still there, but it's just a matter of whether it's your turn. Every time I think I'm holding onto faith, it turns into internal friction.
Enliven Therapeutics
ELVN----
Share your thoughts
Write something you'd like to share with our community...